Made-in-Israel anti-viral nasal spray found effective against COVID
Enovid anti-viral nasal spray
(photo credit: Courtesy)
Enovid, a spray developed in Canada by SaNOtize and manufactured in Israel has been found to reduce viral loads in confirmed COVID-19 cases by 95% in 24 hours and 99% in 72 hours
An anti-viral nasal spray called Enovid that was developed in Canada and tested in the UK can reduce the viral loads in confirmed COVID-19 cases by 95% in 24 hours and 99% in 72 hours, a press release said on Sunday.
The Israeli-manufactured spray can be used up to five times a day after coming in contact with viruses, according to the release. It's suitable for children as young as 12 years old, and the Ministry of Health approved it in January this year. It will go on sale in the coming week.
"The spray we developed has been proven not only as a virus blocker that causes Covid-19 but also as a killer," Dr. Gili Regev, CEO and founder of Snotize (the company that developed the spray) said.
Since most COVID-19 infections are nasal, SaNOtize believes this is an effective way to reduce the spread and infection of COVID-19. It has been able to suppress the SARS-CoV-2 virus within two minutes, including the Alpha and Gamma variants, according to the release. It is currently being tested against the Delta variant.
The spray employs nitric oxide as a mechanical and chemical barrier against viral infection in the nose, which is where respiratory diseases like COVID-19 infiltrate the body.
The spray is also effective against other respiratory viruses such as those that cause flu.